ADAMTS13 treatment to enhance graft survival
AssigneeChildren's Medical Center Corporation
InventorsDenisa D. Wagner, Siu Ling Wong
Life of this patent
Estimating the term…
Abstract
The disclosure provides a method for treating and/or preventing graft rejection with A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMT S13). The disclosure provides a method for increasing ADAMTS13-mediated von Willebrand factor (VWF) cleavage in a subject that received a graft by administering ADAMTS13. The disclosure also provides a method of determining the likelihood that a subject will rejection a graft.
Claims18
A method for treating or preventing graft rejection in a subject that received a skin graft, the method comprising administering to the subject in need thereof a therapeutically effective amount of a composition comprising A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13), wherein administering ADAMTS13 reduces and/or prevents neutrophil extracellular trap (NET) burden in the skin graft.
Dependencies are inferred from the claim text.